Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

382
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
382
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

321
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
321
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

540
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
540
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

419
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
419
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
189

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Decoding the complexity of intestinal immunity with spatial transcriptomics.

Current opinion in immunology·2026
Same author

Promoting intestinal regeneration without tumor risk in immune-mediated inflammatory diseases.

Trends in immunology·2026
Same author

Spatiotemporal analysis reveals distinct inflammatory programs underlying chronic colitis.

Immunity·2026
Same author

TNFα signaling in radiation-induced chronic bowel dysfunction suggests therapeutic potential for IBD biologics.

Molecular medicine (Cambridge, Mass.)·2026
Same author

Uncovering Immune Niches in Health and Disease Using Spatial Transcriptomics.

European journal of immunology·2026
Same author

IL-26 from innate lymphoid cells regulates early-life gut epithelial homeostasis by shaping microbiota composition.

The EMBO journal·2025

関連する実験動画

Updated: Sep 10, 2025

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

2.7K

炎症性腸疾患におけるB細胞

Francisca A Castillo1, Bianca C Kern1, Eduardo J Villablanca1

  • 1Division of Immunology and Respiratory Medicine, Department of Medicine, Solna, Karolinska Institutet and University Hospital, Stockholm 17176, Sweden; Center of Molecular Medicine, Stockholm 17176, Sweden.

Immunology letters
|August 22, 2025
PubMed
まとめ

B細胞は炎症性腸疾患 (IBD) で複雑な役割を果たし,伝統的なT細胞の焦点を超えています. これらの多様なB細胞の機能を理解することは IBDの標的治療の開発の鍵です.

科学分野:

  • 免疫学
  • 胃腸内科
  • 細胞生物学

背景:

  • 炎症性腸疾患 (IBD) は歴史的にT細胞媒介と考えられてきました.
  • 慢性腸炎におけるB細胞の有意な関与を新鮮に示しています.
  • B細胞は通常,腸の免疫受容性と粘膜の健康を支える.

研究 の 目的:

  • IBDの病原性におけるB細胞の役割に関する理解の進化をレビューする.
  • 特定のB細胞サブセットを標的とした選択的な治療戦略の必要性を強調する.
  • B細胞のダイナミクスに基づいた正確な免疫療法の可能性を探求する.

主な方法:

  • IBDにおけるB細胞生物学に関する現在の科学文献のレビュー.
  • 腸炎におけるB細胞機能を示す実験モデルを分析する.
  • B細胞を標的とする治療に関する臨床観察の議論

主要な成果:

  • プラズマ細胞の増加と抗体反応の変化により,IBDではB細胞区画が著しく変化します.
  • Sca1+PD-L1+B細胞のような 炎症を誘発するB細胞のサブセットが IBDの間に現れる.
  • 実験モデルでは,IBDにおけるB細胞の有害な役割と有益な役割の両方を示しています.
キーワード:
抗体B セル炎症性腸疾患プラズマ細胞三次リンパ性構造

さらに関連する動画

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.2K
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

16.8K

関連する実験動画

Last Updated: Sep 10, 2025

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

2.7K
Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.2K
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

16.8K
  • 広範なB細胞減少療法 (例:リトゥキシマブ) の限られた有効性は,複雑性を示唆する.
  • 結論:

    • B細胞はIBDにおいて多面的な役割を果たし,病原性および調節性両方の役割を果たします.
    • 有害なB細胞を標的にし 有益なB細胞を保存する 選択的な治療法が必要です
    • 腸内B細胞の空間的,現象的,時間的動態に関するさらなる研究は,効果的なIBD免疫療法の開発に不可欠です.